Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230211 | 0.98 | KEAP1 (0.56) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL231117 | 0.98 | KEAP1 (0.56) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL232389 | 0.98 | KEAP1 (0.56) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL233216 | 0.98 | KEAP1 (0.56) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL5390103 | 0.98 | KEAP1 (0.56) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL10889066 | 0.98 | KEAP1 (0.56) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL231245 | 0.98 | KEAP1 (0.56) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL7670406 | 0.98 | KEAP1 (0.56) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL231271 | 0.93 | KEAP1 (0.60) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 | |
| SCHEMBL7239607 | 0.87 | KEAP1 (0.71) | KEAP1SMN1; SMN2HPGDDUSP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109096227-B | Caprolactone-modified 3, 4-epoxy cyclohexyl methyl-3 ', 4' -epoxy cyclohexyl formate and preparation method thereof | 江苏泰特尔新材料科技股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-113372827-A | Special packaging adhesive film for heterojunction battery and preparation method thereof | 浙江祥邦科技股份有限公司 | 2021-09-10 | — | — | CN | claimed |
| CN-110804410-A | High-temperature-resistant and high-humidity-resistant epoxy resin composition for packaging LED (light emitting diode) products | 安徽众博新材料有限公司 | 2020-02-18 | — | — | CN | claimed |
| CN-109020945-A | A kind of different gamboge amphyl, preparation method and application | 贵州省中国科学院天然产物化学重点实验室 | 2018-12-18 | — | — | CN | claimed |
| US-20120232077-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | ACURX PHARMACEUTICALS, LLC | 2012-09-13 | — | — | US | claimed |
| EP-2475252-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | Glsynthesis Inc. (US) | 2012-07-18 | — | — | EP | claimed |
| WO-2011031935-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | GLSYNTHESIS INC. (US) | 2011-03-17 | — | — | WO | claimed |
| WO-2004056353-A2 | DEVICE AND METHOD FOR DELIVERING MMP INHIBITORS | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | claimed |
| US-5304549-A | Control or prevention of degenerative joint diseases | HOFFMANN-LA ROCHE INC. (US) | 1994-04-19 | — | — | US | claimed |
| EP-0497192-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-08-05 | — | — | EP | claimed |
| US-20240174675-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-05-30 | — | — | US | disclosed |
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| CN-117177958-A | Small molecule modulators of alveolar type 2cell proliferation for the treatment of pulmonary diseases | 斯克里普斯研究学院 | 2023-12-05 | — | — | CN | disclosed |
| EP-4281439-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | The Scripps Research Institute (US) | 2023-11-29 | — | — | EP | disclosed |
| EP-0497192-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1992-08-05 | — | — | EP | disclosed |
| EP-0450066-A1 | CARBOSTYRIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-09 | — | — | EP | disclosed |
| EP-0424816-A2 | Bismaleimide resin compositions | POLYSAR LIMITED (CA) | 1991-05-02 | — | — | EP | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
| US-4207110-A | 2,5-DIALKOXY-4-MORPHOLINO-BENZENE DIAZONIUM SALT AND COUPLER COMBINATION TO GIVE BLACK IMAGE | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232077-A1 | SELECTIVE ANTIBACTERIALS FOR CLOSTRIDIUM DIFFICILE INFECTIONS | MRPL21, RPN2, ALPI | KEAP1 2149/4885SMN1; SMN2 4154/4885HPGD 895/4885 |
| US-20240174675-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | DPP4, DPP7, DPP3 | KEAP1 1566/4885SMN1; SMN2 2570/4885HPGD 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.